Indaptus Therapeutics Inc (INDP): שווי כולל של נכסי החברה

Indaptus Therapeutics (INDP) is developing innovative non-pathogenic bacterial systems (including decOyp) to combat tumors, leveraging clinical trial results and M&A potential. The use of inactivated bacteria provides the company with patent protection and pricing power within the oncology sector. The share price retrospective demonstrates total assets at 9.41, while demand for such immunotherapeutic platforms is currently being shaped through clinical testing.

Total assets represent the aggregate of the company's resources, calculated reverse-engineered through return on assets (ROA) to identify hidden business degradation, while analyzing the organization's asset volume allows for an assessment of balance sheet stability against a critically short cash runway and high safety risks associated with the early-phase trials of Indaptus Therapeutics (INDP) anti-tumor platforms.